| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 286,497 | 193,618 | ||
| Marketable securities | 1,629,213 | 1,527,619 | ||
| Accounts receivable | 0 | 0 | ||
| Prepaid expenses and other current assets | 13,382 | 12,429 | ||
| Total current assets | 1,929,092 | 1,733,666 | ||
| Total property and equipment, gross | 206,444 | - | ||
| Accumulated depreciation | 85,613 | - | ||
| Property and equipment, net | 120,831 | 124,926 | ||
| Marketable securities, non-current | 28,412 | - | ||
| Restricted cash | 8,006 | 8,006 | ||
| Operating lease assets | 134,659 | 137,641 | ||
| Other non-current assets | 24,308 | 25,472 | ||
| Total assets | 2,245,308 | 2,029,711 | ||
| Accounts payable | 11,798 | 9,753 | ||
| Accrued expenses | 84,182 | 73,738 | ||
| Deferred revenue, current | 1,295 | 2,129 | ||
| Accrued tax liabilities | 3,426 | 715 | ||
| Operating lease liabilities | 18,256 | 18,027 | ||
| Other current liabilities | 0 | 0 | ||
| Total current liabilities | 118,957 | 104,362 | ||
| Deferred revenue, non-current | 12,323 | 12,323 | ||
| Operating lease liabilities, net of current portion | 192,768 | 197,425 | ||
| Other non-current liabilities | 5,278 | 4,476 | ||
| Total liabilities | 329,326 | 318,586 | ||
| Common shares, chf 0.03 nominal value, 132,477,166 shares authorized at september 30, 2025 and at december 31, 2024, 93,998,110 and 85,912,297 shares issued at september 30, 2025 and december 31, 2024, respectively, 93,872,794 and 85,741,981 shares outstanding at september 30, 2025 and december 31, 2024, respectively | 3,013 | 2,794 | ||
| Treasury shares, at cost, 125,316 and 170,316 shares at september 30, 2025 and december 31, 2024, respectively | 60 | 62 | ||
| Additional paid-in capital | 3,724,981 | 3,414,849 | ||
| Accumulated deficit | -1,816,938 | -1,710,497 | ||
| Accumulated other comprehensive income | 4,986 | 4,041 | ||
| Total shareholders' equity | 1,915,982 | 1,711,125 | ||
| Total liabilities and shareholders equity | 2,245,308 | 2,029,711 | ||
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)